An interventional study of Exercise and Control in Non-Small Cell Lung Cancer, Exercise Training and Immunotherapy, sponsored by Medical University of Graz. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Medical University of Graz · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies in Carcinoma, Non-Small-Cell Lung with a site in Austria — 39 open to participants now, 72 under way, 46 of them phase 3. Carcinoma, Non-Small-Cell Lung · Austria.
Among the 174 studies in Carcinoma, Non-Small-Cell Lung with a site in Austria, this one is the 139th largest by planned enrollment of the 159 interventional ones that give a count, is one of 9 that started in 2026, is one of 4 with no phase, reaches primary completion later than 43 of the 71 other live ones, and was the 169th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →39 of the 174 studies in Carcinoma, Non-Small-Cell Lung with a site in Austria are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Austria, United States, Argentina and 10 more countries
Ages 18+
Eikon Therapeutics · Sites in Austria, United States, Argentina and 11 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Austria, United States, Argentina and 29 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Austria, United States, Argentina and 33 more countries
Ages 18+
Boehringer Ingelheim · Sites in Austria, United States, Argentina and 25 more countries
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 42 · Phase 3 104 · Phase 4 3
First in 1995; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 490 across the 159 interventional studies, 250 across the 14 observational. Of the 94 that completed or were terminated, 70 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
146 of 174 have an industry lead sponsor. The 10 most frequent:
Medical University of Graz is the lead sponsor of 471 studies on the registry; 98 are open to participants now.
Medical University of Graz has 1 study filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
14 of the studies in Carcinoma, Non-Small-Cell Lung with a site in Austria that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06140836Phase 3Bristol-Myers SquibbA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | 2027-02-16 |
| NCT06726265Phase 3Immutep S.A.S.Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) | 2027-06 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06452277Phase 3BayerA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | 2027-10-28 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
Add all 14 to your calendar (.ics) → With an account.
Among the 174 studies in Carcinoma, Non-Small-Cell Lung with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project is about the effect of a 12-week training therapy intervention in patients suffering from non-small cell and small-cell lung cancer. It has widely been accepted that exercise is preventive against certain types of cancer. Individuals following an active lifestyle have a significantly lower risk for several chronic diseases, including cancer, as compared to sedentary ones. However, evidence is still lacking for exercise as part of routine cancer treatment. It has widely been accepted that exercise strongly impacts immune response, and might influence antitumor immune response as well. In this study, patients suffering from lung cancer undergo either a 12-week training program consisting of moderate-intensity continuous exercise (MICE), or a 12-week program with high-intensity interval exercise. Both groups will be compared to a control group receiving standard exercise recommendations. The immunologic response, i.e. cytokine profiles and changes in peripheral blood mononuclear cell (PBMC) characteristics will be the main endpoint. Blood will be taken from the patients at different timepoints, and blood samples will be tested for these immunologic changes. FACS analysis will be used to assess the properties of immune cells and potential changes upon the exercise regimen. Mitochondrial function will be assessed via the Seahorse machine, and mass spectrometry (lipidomics) will be used for the analysis of lipid profile changes.
Lung cancer is the number one cause of cancer-related deaths worldwide. A few decades ago, the prognosis at lung cancer first diagnosis was generally poor with only a few months of median survival. New treatment regimens have markedly improved survival times - especially in certain histologic and molecular pathologic subtypes. The positive effect of exercise on the incidence of several cancer entities such as colorectal- or breast cancer, has been demonstrated previously. Physically active individuals are diagnosed with cancer significantly less often as compared to sedentary people. In oncologic follow-up care, a positive effect of exercise and training with an advantage in survival has also been proven, e.g. in breast cancer patients.
In addition, existing data shows a positive effect of exercise on the immune system: active individuals show a different pattern of proinflammatory markers in the blood serum, with every exercise session generating an immune-stimulatory effect which changes the immunologic serum profile also at rest. Thus, regular exercise has an anti-inflammatory long-term effect.
Hypothesis and Objectives: With this project the investigators seek to demonstrate distinct immunologic changes, assessing cytokine serum profiles and changes in peripheral blood mononuclear cell (PBMC) characteristics upon a medically guided training regimen. The investigators assume that the antitumor immune response is positively affected by the training therapy regimen.
Setting and Methods. To exactly define "exercise" in this setting, as a first step the investigators will test two exercise types in healthy individuals. According to the individual exercise capacity as determined by spiroergometry, healthy subjects will either perform moderate-intensity continuous exercise (MICE), or a high-intensity interval training (HIIT). By means of venous blood sampling before and after training the investigators determine the respective changes of serum immune markers through exercise. The same two training types will then be performed by lung cancer patients upon immunotherapy, with one patient group doing MICE-sessions, one group doing the HIIT and a third group who will receive general exercise recommendations but otherwise will not undergo supervised training. Inflammatory serum parameters and PBMC characteristics will be compared between the groups. Moreover, the overall aerobic capacity (and respective changes before and after the training intervention), as well as quality of life will be analysed.
Patients in the exercise groups will be advised to train once a week under medical supervision, and to walk briskly for 30 minutes every day of the week in addition. The investigators' hypothesis is, that exercise should be implemented as a complementary treatment strategy in the lung cancer treatment setting, possibly improving not only physical health and wellbeing but also treatment response. In addition to improving the patients' quality of life by a better physical capacity and fitness, helping the participants in everyday activities, the investigators propose that the implementation of exercise programs in various oncologic settings in future may improve the patients' outcome.
Scientific Novelty. Standardization of exercise regimens in oncologic scenarios in the existing literature is generally poor. The investigators carry out one of the few studies where the type, duration, timing and intensity of exercise in both exercise groups is clearly defined according to the F.I.T.T. (frequency, intensity, type, time)-principle, comparing two different training modalities to sedentary control patients, respectively. Exercise needs to be seen as a drug, and like in any drug the optimum dose must be clearly outlined.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this arm will undergo a 12-week training therapy regimen consisting of twice weekly supervised moderate-intensity continuous exercise (MICE) and home-based walking exercise for 30 minutes, five times a week, in addition.
Behavioral: Exercise
Patients in this arm will undergo a 12-week training therapy regimen consisting of twice weekly supervised high-intensity interval exercise and home-based walking exercise for 30 minutes, five times a week, in addition.
Behavioral: Exercise
Patients in this arm will receive general recommendations on an active lifestyle, but will not take part in supervised training sessions and are not asked to do home-based exercise either.
Other: Control
1 study arm doing continuous type exercise will be compared to 1 study arm doing high-intensity interval exercise, over the course of 12 weeks, respectively. Both arms will be compared to sedentary control patients.
Also known as: Home-based walking exercise
For patients in the control group, general exercise recommendations (e.g. recommendations by the CDC suitable for all adult individuals) will be given, however, no training therapy intervention is done and no home-based walking exercise is required either.
FACS analysis of PBMCs
The FACS panel comprises: CD4pos Helper T Cells, CD8pos Cytotoxic T Cells, Regulatory T Cells, Effector Memory T Cells, Naive/Memory Subsets, Activated/Exhausted T Cells, gamma-delta T Cells, Naive B Cells, Memory B Cells, Transitional B Cells, Classical Monocytes, Intermediate Monocytes, Non Classical Monocytes, NK CD16pos, NK CD16neg, Neutrophils, Basophils, Mast Cells, Viable vs. Dead Cells, Immune Checkpoint Subsets, Activation/Proliferation Markers. The total numbers and percentages of cells positive for the above listed markers are the primary outcome measures. The surface marker profile of PBMCs as a whole will define the outcome, showing differences between exercising and sedentary patients, e.g.: "In patients from the exercise group, XX% of naive B cells were found, and XX% of CD4pos Helper T Cells, and XX% CD8pos Cytotoxic T Cells were found. In patients from the control group, the proportion of naive B cells was XX...".
Time frame: Before and after the 12 week training therapy intervention, i.e. differences seen between 12 and 14 weeks
Cytokine analysis from peripheral blood sampling
IFN gamma, IL-13, GM-CSF, IL-1β, IL-5, sCD25 (IL-2Ra), IL-4, VEGF, IL-17A, IL-18, CCL4 (MIP-1β), IL-15, IL-12p70. The count of the above listed cytokines in pg/ml will be recorded in venous blood samples, with higher values after exercise indicating a more pronounced inflammatory response. Blood plasma samples from the patients will be collected at the beginning and after the 12 weeks exercise intervention for cytokine testing. Additionally, cytokine profiling will be done before and after one exercise bout to illustrate acute changes. Multiplex detecton kits (Legendplex) will be used for cytokine profiling. For every cytokine, differences will be recorded in one patient at enrollment and after completion of the 12 week training therapy. Differences between the exercising and non-exercising patients will be recorded as well. E.g. "IFNgamma levels were on average XX pg/ml before the intervention. After the intervention period of 12 weeks, IFNgamma levels were on average XX pg/ml."
Time frame: From enrollment to after the 12 week intervention, i.e. a period between 12-14 weeks
Number of participants with changes in mitochondrial function (Seahorse analysis)
Mitochondrial function parameters are combined to assess how well mitochondria work in a given patient. Oxygen Consumption Rate (OCR), Extracellular Acidification Rate (ECAR), Glycolytic Rate, Glycolytic Capacity, Basal Oxygen Consumption Rate, Maximal Respiration, and Spare Respiratory Rapacity are assessed by means of a Seahorse assay using a Seahorse XF Analyzer from Agilent, that measures the real-time metabolic activity of live cells by simultaneously assessing mitochondrial respiration and glycolysis. The number of patients with changes in oxygen consumption rate (OCR), which indicates mitochondrial respiration, and the extracellular acidification rate (ECAR), which is linked to glycolysis, is analysed. Aberrations in mitochondrial function as well as changes from before to after the intervention in % of patients / total number of patients is assessed.
Time frame: From enrollment to after completion of the exercise intervention, i.e. a period between 12-14 weeks
Mass spectrometry - Lipidomics
Marker Name (or m/z value), Retention Time and Intensity/Abundance of a given metabolite will be analysed in plasma samples. Markers comprise H4CH, H4A1, H4A2, TPA1, HDA1, IDPL, H4PL, Glutamine, L5CH, H3CH, TPA2, HDA2, L5PL, HDCH, H3A2, TPCH, L5PN, L5AB, V1FC, H3FC, L5FC, SPC, IDTG, V5FC, Glutamic acid, H4FC, Alanine, HDPL, V2PL, Glucose, LDCH, L4CH, H3A1, L4FC, V2TG. Lipidomics is used to describe the complete lipid profile within the patients' immune cells. It is a subset of the "metabolome". As opposed to classic analysis of carbohydrate metabolism, lipids are more stable, allowing for an analysis of frozen PBMCs. Our hypothesis is that upon the exercise program, lipidomics of the immune cells significantly change, allowing for a more favorable antitumor immune response. Total counts of each above-listed metabolite in the blood will be determined, e.g. in milligrams per deciliter and for every metabolite, changes between exercising and sedentary patients are recorded.
Time frame: From enrollment to after completion of the 12 week exercise intervention, i.e. a time period between 12 and 14 weeks
Aerobic capacity
With spiroergometry testing at the beginning of the exercise program and after completion of the program at 12 weeks, the investigators will assess potential changes in the patients' aerobic capacity. The normal range for womens' VO2max starts at 30 ml/kg/min and for men at 35 ml/kg/min with lower ranges expected in the usually elderly tumor patients. Improvements over the 12 week intervention period will be recorded.
Time frame: From enrollment to after completion of the 12 week training therapy intervention, i.e. a time period between 12 and 14 weeks
Quality of life - EORTC-QLQ C30 (German version)
The patient's quality of life will be assessed by two questionnaires, one for quality of life in cancer patients in general and one questionnaire specifically for lung cancer. The EORTC-QLQ C30 (German version) has a range from 0-100 with higher values representing a better quality of life. Minimal Important Difference (MID): A change of 5 to 10 points is generally considered clinically meaningful. Differences of 10 points are often used to indicate clinical relevance.
Time frame: From enrollment to after completion of the 12 week training therapy intervention, i.e. a period between 12 and 14 weeks
Quality of life - FACT-L scale (German version)
The FACT-L (Functional Assessment of Cancer Therapy-Lung) questionnaire has a maximum possible total score of 0 to 136, which includes the 27-item FACT-G (general) and the 9-item Lung Cancer Subscale (LCS). Higher scores indicate better quality of life.
Time frame: From enrollment to after 12 weeks, i.e. a period between 12 and 14 weeks
Bodycomposition / Bioimpedance measurement
Bioimpedance measurement will be used to determine body composition (and possible increments in muscle mass). The measures are given in % of total body mass. Higher values of muscle mass are generally considered better and indicate a good response to training, whist declines in muscle mass are often observed in inactive cancer patients.
Time frame: Enrollment to after 12 weeks, i.e. a period between 12 and 14 weeks
Plan to share: Undecided — It depends on the data that is measured, especially as far as the basic research experiments (FACS, Seahorse, Cytokines, Lipidomics) are concerned. If the data is promising, we might share it with other researchers for additional publication.
Started Apr 2026 (actual). Primary completion is estimated for Oct 2028, 30 months after the start.
Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 30 months is below that.
Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →